retatrutide dosage trial just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric ESC 2024: Retatrutide improves lipid

Shifting focus from the brands original fiber powders to a capsule formula, ColonBroom targets natural approach to induce GLP-1 release

doi:10.1101/gr.143000

This approval expands treatment options for patients living with diabetes in India

A JAMA Network Open retrospective cohort study of 125,474 adults with overweight or obesity: Patients with T2DM: 46.5% discontinued by year one 64.1% discontinued by year two Patients without T2DM: 64.8% discontinued by year one 84.4% discontinued by year two Nearly 85% of patients without diabetes stopped taking GLP-1s within two years

are supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (NIHR203316)

But the effects aren't even across the industry, and "certain categories are more impacted than others," Johnson said